Close Menu

NEW YORK (GenomeWeb) – Alveo Technologies, a pre-clinical stage medical diagnostics firm, announced today that it has raised $38 million in Series A financing.

The Alameda, California-based startup, which was founded in 2014, said it plans to use the funding to advance the optimization and commercialization of its rapid diagnostic platform for infectious diseases. The firm's technology combines nucleic acid detection with molecular biochemistry in order to identify such illnesses.

To read the full story....

...and receive Daily News bulletins.

Already have a GenomeWeb or 360Dx account?
Login Now.

Don't have a GenomeWeb or 360Dx account?
Register for Free.

In a letter, about two dozen researchers criticize the World Health Organization investigation into the origins of SARS-CoV-2 and call for a new inquiry, the Wall Street Journal reports.

National Geographic reports that nine great apes at the San Diego Zoo have been vaccinated against SARS-CoV-2.

Janet Woodcock, the acting commissioner of the US Food and Drug Administration, speaks with NPR about SARS-CoV-2 testing and vaccines in the US.

In Science this week: genetic study of kidney fibrosis implicates the SOX9-NAV3-YAP1 axis.